Given that EVs are currently being investigated in immune regulation, as diagnostic biomarkers of disease (in both BC and OS)32–34, and developed as EV-based targeted immunotherapies, we utilized a panel of OS and BC cell lines with varying metastatic potential and examined the contribution of IRF5 to EV-mediated PMN formation and metastasis. This evidence concerns the gene IRF5 and breast cancer.